In this podcast, Susan Hutchinson, MD, discusses the implications for her team's research presented in the session "Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study" at the American Academy of Neurology's 2021 Virtual Annual Meeting.